GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » E10

TGTX (TG Therapeutics) E10 : $-1.99 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

TG Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $0.020. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.99 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 58.80% per year. During the past 5 years, the average E10 Growth Rate was 52.00% per year. During the past 10 years, the average E10 Growth Rate was 44.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of TG Therapeutics was 63.10% per year. The lowest was 20.40% per year. And the median was 37.80% per year.

As of today (2024-12-13), TG Therapeutics's current stock price is $31.63. TG Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-1.99. TG Therapeutics's Shiller PE Ratio of today is .


TG Therapeutics E10 Historical Data

The historical data trend for TG Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics E10 Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.43 -29.85 -2.15 -2.11 -2.08

TG Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.10 -2.08 -2.09 -2.05 -1.99

Competitive Comparison of TG Therapeutics's E10

For the Biotechnology subindustry, TG Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Shiller PE Ratio falls into.



TG Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.02/133.0289*133.0289
=0.020

Current CPI (Sep. 2024) = 133.0289.

TG Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.480 99.070 -0.645
201503 -0.350 99.621 -0.467
201506 -0.380 100.684 -0.502
201509 -0.280 100.392 -0.371
201512 -0.370 99.792 -0.493
201603 -0.280 100.470 -0.371
201606 -0.330 101.688 -0.432
201609 -0.500 101.861 -0.653
201612 -0.480 101.863 -0.627
201703 -0.520 102.862 -0.673
201706 -0.450 103.349 -0.579
201709 -0.480 104.136 -0.613
201712 -0.460 104.011 -0.588
201803 -0.590 105.290 -0.745
201806 -0.590 106.317 -0.738
201809 -0.430 106.507 -0.537
201812 -0.690 105.998 -0.866
201903 -0.430 107.251 -0.533
201906 -0.420 108.070 -0.517
201909 -0.690 108.329 -0.847
201912 -0.440 108.420 -0.540
202003 -0.485 108.902 -0.592
202006 -0.470 108.767 -0.575
202009 -0.730 109.815 -0.884
202012 -0.710 109.897 -0.859
202103 -0.690 111.754 -0.821
202106 -0.590 114.631 -0.685
202109 -0.650 115.734 -0.747
202112 -0.700 117.630 -0.792
202203 -0.510 121.301 -0.559
202206 -0.300 125.017 -0.319
202209 -0.260 125.227 -0.276
202212 -0.390 125.222 -0.414
202303 -0.280 127.348 -0.292
202306 -0.340 128.729 -0.351
202309 0.730 129.860 0.748
202312 -0.100 129.419 -0.103
202403 -0.070 131.776 -0.071
202406 0.040 132.554 0.040
202409 0.020 133.029 0.020

Add all the adjusted EPS together and divide 10 will get our e10.


TG Therapeutics  (NAS:TGTX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


TG Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Executives
Sagar Lonial director C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Laurence N Charney director MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Yann Echelard director C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Sean A Power officer: CFO, Secretary and Treasurer 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss director, officer: CEO and President 750 LEXINGTON AVE, NEW YORK NY 10022
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume director 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u. 10 percent owner 3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum director 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc 10 percent owner 787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019